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ABSTRACT 
The interaction between thorium and human serum components was studied using difference 
ultraviolet spectroscopy (DUS), ultrafiltration and high–pressure–anion exchange 
chromatography (HPAEC) with external inductively conducted plasma mass spectrometry 
(ICP–MS) analysis. Experimental data are compared with modelling results based on the law 
of mass action. Human serum transferrin (HSTf) interacts strongly with Th(IV), forming a 
ternary complex including two synergistic carbonate anions. This complex governs Th(IV) 
speciation under blood serum conditions. Considering the generally used Langmuir-type 
model, values of 1033.5 and 1032.5 were obtained for strong and weak sites, respectively. We 
showed that trace amounts of diethylene triamine pentaacetic acid (DTPA) cannot complex 
Th(IV) in the blood serum at equilibrium. Unexpectedly this effect is not related to the 
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competition with HSTf but is due to the strong competition with major divalent metal ions for 
DTPA. However, Th-DTPA complex was shown to be stable for a few hours when it is 
formed before addition in the biological medium; this is related to the high kinetic stability of 
the complex. This makes DTPA a potential chelating agent for synthesis of 226Th-labeled 
biomolecules for application in targeted alpha therapy. 
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1. Introduction 
The quantitative description of the interactions of thorium (IV) with blood serum components 
is of high relevance for the rational design of molecules suitable for in vivo chelation of 
thorium in medical applications [1, 2] or for decorporation in case of accidental ingestion [3-
5]. In the first case, the chelating agent is used to couple the radionuclide to tumor selective 
carrier molecules to target and destroy cancer cells [6]. Here the Th(IV)-chelate complex is 
formed in vitro before application to the patient. The alpha emitters 226Th (t1/2=31 min) and 
227Th (t1/2=18,7 days) are promising radionuclides for application in targeted alpha therapy 
(TAT) [1, 2, 7]. In the second case, the ligand should target the unwanted metal ion in vivo 
and form soluble complexes which can be excreted via the kidneys.  
Thorium distribution in rats serum was studied by Peter and Lehmann in 1981 [8]. By the 
means of chromatographic studies and competition experiments with iron, the authors 
reported that the binding site of Th(IV) was the iron-binding site of transferrin (HSTf). 
Similar behaviour was reported for different actinides (IV) including Pu(IV) from various in 
vivo and in vitro studies [3, 9-11]. The interaction between Th(IV) and HSTf was further 
studied by Harris et al. [12] by using difference ultraviolet spectroscopy (DUS). As in the 
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iron-transferrin complex, two Th(IV) ions are bound to HSTf protein at the physiological pH. 
Two and one tyrosine groups were proposed to coordinate to thorium in strong C–terminal 
and weak N–terminal sites, respectively. In conclusion, HSTf appears as the main component 
governing Th(IV) speciation in blood serum [13]. An estimation of the complexation 
constants can be obtained by extrapolation from the emprical law presented by Sun et al. [14]. 
However, to the best of our knowledge, they have never been experimentally measured. 
Furthermore, one recent study showed no interaction between Th(IV) and HSTf [15], these 
results being rather conflicting with the others. 
The first objective of the present paper is to complete available literature data to give a 
better comprehensive view of Th(IV) speciation in blood serum. The interaction of Th(IV) 
with HSTf has been studied by Difference ultraviolet spectroscopy (DUS) to determine 
complexation constants. The effect of human serum albumin (HSA) on Th(IV) speciation 
in the blood serum, the second important metallo-protein present in the biological 
medium, has been also estimated. Based on these parameters, and including literature data 
of thermodynamic constant of Th(IV) complexation with low molecular weigh organic 
and inorganic ligands, a model calculation was performed to describe Th(IV) interactions 
in blood serum. The reliability of the simulation is considered regarding the published in 
vivo experimental speciation results [8] and the experimental data from the speciation 
studies realized by High Pressure Anion Exchange Chromatography (HPAEC) with 
inductively conducted plasma mass spectrometry (ICP–MS) detection.  
In addition, the developped model is used in combination with in vitro studies performed 
by ultrafiltration, to assess the efficiency of diethylene triamine pentaacetic acid (DTPA) 
to form stable complexes with Th(IV) under blood serum conditions. DTPA is the chelate 
recommended for the decorporation of Th(IV) [16]. It is not toxic for humans and forms a 
strong complex with Th(IV) [17, 18]. According to the “hard and soft (Lewis) acids and 
 4
bases” (HSAB) therory [19], it presents nitrogen and oxygen atoms suitable for the 
complexation of the “hard” Th(IV) cation and it is well preorganised for the coordination 
of spherical cations. Furthermore, it can be easily attached to a biological vector; this is a 
pre-requisite in TAT and may be useful in chelation therapy. The obtained results are 
discussed to assess the potential use of DTPA as a chelating agent for TAT with 226Th.  
 
2. Materials and methods 
2.1. Reagents 
Human serum transferrin (HSTf, apo–transferrin human ≥ 98%, Sigma) was purified by size–
exclusion chromatography on a PD–10 column using 0.1 M NaCl / 2.10-3 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.4 as an eluent. HSTf 
concentration was determined spectrophotometrically at = 280 nm using 93000 cm-1 M-1 as 
a molar extinction coefficient [20]. Human serum albumin (HSA, albumin from human serum 
≥ 96%, Sigma) was used as received. Human serum was supplied by Lonza and was diluted in 
0.1 M NaCl solution buffered at pH 7.4 equilibrated with 1 % CO2 gas. Th(IV) stock solution 
was prepared by dilution of a standard solution of 232Th (232Th(NO3)4(H2O)4) (from Prodis) to 
obtain a final concentration of 2.10-3 M. Other chemicals were analytical grade. HSTf, HSA 
and carbonate stock solutions were freshly prepared before use.  
 
2.2. Samples preparation 
Solutions were prepared with ultrapure water (MilliQ, 18 MΩ.cm). All experiments were 
performed in solution of pH 7.4  0.1 and ionic strength of 0.1 (NaCl) buffered with 2.10-3 M 
(HEPES) at room temperature (20 ± 2 °C). Samples in the absence of carbonate were 
prepared in a glove box under 100% nitrogen atmosphere. Samples in the carbonate system 
were prepared in a glove box under 99/1% nitrogen/carbon dioxide atmosphere. For the 
 5
complexation study realized as a function of carbonate concentration, the carbonate ion was 
added to the solution prepared under 100% nitrogen atmosphere. The samples were then kept 
closed during the experiment to prevent equilibration with atmospheric CO2. For the 
complexation study realized as a function of phosphate or nitrilotriacetic acid (NTA) 
concentration, the samples were prepared under normal atmosphere. Inorganic carbon 
concentration was determined at equilibrium by total organic carbon analysis (TOC). 
 
2.3. Analytical tools 
pH measurements were performed using a PHM220 from MeterLab. Inorganic carbon 
analyses were done on a TOC–VCSH apparatus supplied by Shimadzu. Thorium analyses were 
performed by ICP–MS using a XSeries 2 provided by Thermo Fisher (sensibility limit of 0.1 
ppb). UV–spectra were recorded on a UV–visible UV–2401 PC spectrophotometer from 
Shimadzu. The centrifugation experiments were performed using a centrifuge RC6 from 
Thermo Fisher at 27000 g. The HPAEC device was a Dionex UltiMate3000 system consisting 
of a DGP–3600 MB pump, an AS3000 auto–sampler, a TCC–3200B column oven and a 
diode array DAD–3000 detector. The stationary phase was a Dionex AS20 anionic exchange 
column (2 mm diameter x 25 cm length), with an AG20 guard column (2 mm diameter x 5 cm 
length). The AS20 consists of a hydrophilic polymer grafted with quaternary alkanol 
ammonium ions. The total capacity represented by both columns is 79 microequivalents. 
 
2.4. Difference ultraviolet spectroscopy (DUS) 
DUS is the most widely used technique to evaluate metal binding to HSTf [21]. Metal 
complexation was estimated from the absorbance measurements using the difference spectra 
of the metal–protein complexes vs. unmetallated apo–protein. Experimental conditions are 
reported in Table 1. The peak area in the range 220–270 nm were monitored to describe and 
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to quantify Th(IV)–HSTf interaction. Equilibrium is established when the absorbance does 
not change during an interval of 2 hours. The error associated to the absorbance was estimated 
as 0.03 based on repetitive experiments. The main advantage of the method is that the 
absorbance signal of HSTf is not influenced by the signals of other ligands which might 
interact with Th(IV) (e.g. carbonate). The interactions of HSA, DTPA and citrate with Th(IV) 
were studied using competitive method with HSTf [22].  
 
2.5. Ultrafiltration 
This technique was used for Th / HSTf (1% CO2) and Th / serum (1% CO2) systems to 
differentiate the fraction of thorium bound to low– and high–molecular weight compounds. 
Experiments were performed in dialysis bags (Microcon Millipore, 3 kDa) and the separation 
was done by centrifugation at 27000 g. Thorium concentration in the filtrates was determined 
by ICP–MS analysis. A blank was systematically done in parallel to assess the amount of 
Th(IV) adsorbed on the membrane. It was assumed that the separation time (typically 30 
minutes) was not sufficient to perturb equilibrium conditions and that the concentration of 
Th(IV) in the filtrate represented the concentration of Th(IV) associated to the low-molecular 
weight compounds (e.g. OH-, CO32-).  
 
2.6. HPAEC analysis 
The eluent at pH 7.4 was a solution of 0.1 M NaCl buffered with 2.10-3 M phosphate buffered 
saline (PBS, that as 10–fold concentrate, contains 0.1 M of sodium phosphate (Na3PO4) and 
9% of NaCl) equilibrated with 1 % CO2 gas controlled by bubbling. The choice of 1 % CO2  
will be explained latter. Samples and eluent were prepared in a glove box under 99/1% 
nitrogen/carbon dioxide atmosphere. The anion exchanger was pre–equilibrated with the 
eluent before starting the experiments. Samples were injected into the column through a 50 
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µL sample loop injector, with a flow rate of 350 µL.min-1. Proteins and serum were detected 
spectrophotometrically at 280 nm. Th(IV) concentration was determined from collected 
fractions by ICP–MS analysis. 
 
2.7. Modelling 
Computer simulations were performed with the PHREEQC program [23]. Stability constants 
for metal ion complexes in solution are reported in Table 2 and were taken from NEA–OECD 
compilation [24] (complexation of Th(IV) with inorganic ligands), IUPAC [17], NIST 
database [18] (Th(IV) / DTPA) and from [25] for citrate and [26] for NTA. The pKa values of 
sulphates and phosphates ions given by PHREEQC database were taken into account. The 
constants given in the NIST database at an ionic strength () of 0.1 M were extrapolated at 
zero ionic strength using the truncated Davies equation [27].  
The complexation of Th(IV) with HSTf was described with the model proposed by Montavon 
et al. [28]. The interaction between Th(IV) and HSTf was described by using two binding 
sites at the protein surface ( S HSTF 1  and SHSTF 2  ). Any metal ion considered [21], the 
stability constants for interaction with the binding sites differ by approximately one unit of 
their log K value, the difference being probably related to outer–sphere effects [22]. This ratio 
of 10 for K was set as a fixed parameter in the fitting of our experimental data. Consequently, 
the formation of the complex has been described as: 
22
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Where S HSTF 1  and SHSTF 2   represent the strong and weak binding sites, respectively, 
and the charge of -2 relates to the two deprotonated tyrosine groups. 
Alternatively modelling was also performed using the Langmuir-type model generally used in 
the literature. The model takes into account the metal ion speciation and the presence of two 
binding sites at the protein surface: 
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The constants log K1=19.3 and log K2=18.2 have been extrapolated from the empirical 
expression given in [29] and derived from the work presented in [14]. A similar Langmuir–
type model was used to described Th(IV)/HSA interaction with the consideration of one 
binding site. 
In conclusion, for the two studied systems Th(IV)/HSTf and Th(IV)/HSA, there is only one 
unknown parameter (complexation constant) to be determined. The fitting of experimental 
data was done “by hand”. 
 
3. Results and discussion  
3.1. Binding of Th(IV) to protein 
3.1.1. Binding of Th(IV) to HSTf  
Complexation of Th(IV) with HSTf did not occur under physiological–type conditions 
(pH=7.4, 0.1 M NaCl) when precaution was taken for avoiding equilibrium with atmospheric 
CO2. HSTf was not able to compete with OH- in the main Th(OH)4 and (Th)4(OH)12+4 forms. 
To complex Th(IV), a synergistic anion was therefore considered in the present work, starting 
with the NTA, the one used by Harris et al. and Jeanson et al in previous studies [12, 15]. The 
second one corresponds to carbonate, CO32- being the synergistic anion allowing the 
complexation with iron and other metal ions [21]. Finally, the third one is HPO42-, phosphate 
ions being present in the blood serum and being known to be a strong complexing agent for 
Th(IV) in environmental samples [30]. 
Complexation as a function of NTA concentration has been first investigated. The 
complexation kinetic was very slow; more than 4 days were necessary to reach equilibrium 
between Th(IV) and HSTf. The experimental data are presented in Figure 1. The 
complexation with HSTf starts above 10-6 M to reach a maximum of complexation at about 
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10-4 M, corresponding to an absorbance at 242 nm of 0.28. The start of this increase coincides 
with the significant formation of Th(L)22- species (L=deprotonated NTA) in the absence of 
HSTf (figure 1A). Our data are coherent with the one reported by Harris et al. (figure 1B). 
Above 10-4 M, the decrease in absorbance indicates dissociation of the Th–HSTf complex 
arising from the increasing competition between free NTA and HSTf for Th(IV) as NTA 
concentration increases.  
Complexation as a function of carbonates concentration has been investigated in a second 
step. Kinetic of complexation was more rapid than in the presence of NTA (30 hours vs 4 
days). The experimental data are presented in Figure 2B. In the carbonate concentration range 
from 0 to 10-4 M, no complexation between Th(IV) and HSTf has been observed. The 
complexation with HSTf starts for a carbonate concentration above 10-4 M, until a plateau is 
reached corresponding to an absorbance of 0.47. It is worth saying that the complexation 
coincides with the significant formation of the ternary complex Th(OH)2(CO3)22- in the 
absence of HSTf (figure 2A).  
Complexation as a function of phosphate concentration has also been studied. In the 
concentration range from 0 to 10-2 M, no complexation was observed between Th(IV) and 
HSTf even after 2 weeks of equilibration (data not shown). Unlike NTA and carbonate, 
phosphate does not act as synergistic anion. 
A quantitative analysis of experimental data obtained with NTA and carbonates was done as 
follows: the shape of the curves was reproduced by varying the values of the complexation 
constants between Th(IV) and HSTf and the conversion of absorbance in concentration was 
done considering a proportionality according to the Lambert–Beer–law (Figures 1C and 2C). 
In the case of NTA system, we considered the possible formation of ThL22-, the main species 
existing under our conditions. A curve similar to that experimentally observed in the presence 
of carbonate is predicted with the occurrence of a plateau for the highest NTA concentrations 
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studied. The decrease of complexation observed above NTA concentration of 10-4 M can be 
quantitatively explained considering the complexation of HSTf with one Th(IV) and one 
ligand L3-. A good agreement between the experiment and the modelling was obtained with 
K1 = 1031 and K2 = 1030, provided that the maximum of complexation / absorbance observed 
corresponds to 40 % of Th(IV) complexed to the protein (figure 1C). 
For the carbonate series, we first considered the formation of a ternary complex involving one 
carbonate ion, as it is the case for Fe(III) or U(VI) [21, 28]. The increase of complexation can 
be relatively well reproduced till a carbonate concentration of 10-3 M with stability constants 
of log K1 = 27 and log K2 = 26 for strong [31] and weak sites, respectively. At higher 
carbonate concentrations, the fraction of HSTf bound to Th(IV) is expected to decrease, due 
to increasing competition of carbonate with HSTf for Th(IV) complexation leading to the 
complex Th(OH)2(CO3)22- (dotted line in Figure 2C). A much better agreement was obtained 
with two carbonate ions acting as synergistic anions: both the increase of the curve and the 
plateau were well described by simulation with log K1 = 33.5 and log K2 = 32.5. This 
complexation might result from the complexation of the existing species Th(OH)2(CO3)22- 
after release of two hydroxide groups. It is important to notice, that the agreement between the 
experiment and the theory is good provided that we consider 24% of Th(IV) not bound to the 
protein on the plateau (figure 2C). This was confirmed experimentally by ultrafiltration 
experiments; 17 ± 2 % of Th(IV) passed through the membrane and was therefore not bound 
to the protein.  
The analysis of the data shows that the nature of the ternary complexes and the associated 
stability constants rely on the quantitative description of Th(IV) interaction with low-
molecular weight compounds. We can finally calculate for the complexes 2:1 Th(IV):HSTf 
apparent absorptivities normalized with respect to HSTf concentration (obs ) of = 60±7 and 
65±8  103 M-1 cm-1 for carbonate and NTA systems, respectively. The value obtained for the 
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carbonate system was used to simulate the titration curve of HSTf with Th (Figure 2D). The 
determination of similar values, within experimental errors, is in agreement with the fact that 
the absorption band is linked to the interaction of the metal ion to the phenolic groups of the 
tyrosine residues which is expected similar in the two studied systems. The difference in type 
and number of synergistic anions coordinated in the first coordination sphere do not 
contribute to the extinction coefficient. 
Interaction of Th(IV) with HSTf, compared to the interaction U(VI)-HSTf or Fe(III)–HSTf, 
seems to be different. First, two carbonates are necessary to bind to Th(IV), whereas only one 
synergistic ion is necessary for most the metal ions, like Fe(III) or U(VI). Secondly, kinetics 
of complexation at HSTf surface are slow for Th(IV), whereas they are rapid for Fe(III) or 
U(VI) (only 20 min for U(VI) binding vs 30 h for Th(IV)) [28, 31]. It is worth saying that the 
absence of complexation between Th(IV) and transferrin observed by Jeanson et al [15] is 
certainly due to a kinetic problem; Th and HSTf were contacted only for a few hours. Several 
parameters may explain these differences between Th(IV) and Fe(III) binding. The ionic 
radius, for example, being much higher for Th (r = 105 pm) than for Fe (r = 65 pm) [32], the 
penetration of Th(IV) into the lobe of the protein may be more difficult resulting into slower 
kinetics. Moreover, the coordination number is 8 for Th(IV), whereas it is of 6 for Fe. In both 
the N– and C–terminal binding sites of HSTf, the metal ion is coordinated by four groups: two 
tyrosines, one histidine, and one aspartic acid providing four coordination sites for the metal. 
Th(IV) with a coordination number of 8, needs to complete its coordination sphere with four 
other coordinating groups, e.g. by two synergistic carbonates, in a bidendate mode of 
coordination. Fe, to complete its coordination sphere, needs only one carbonate. The 
occurrence of only one synergistic anion coordinated in the presence of NTA may result from 
steric effects, NTA being larger than carbonate. 
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The experiments reported in the following part have been realized at a carbonate 
concentration of 5.10-3 M (1 % CO2), where maximal complexation between Th(IV) and 
HSTf occurs. 
 
3.1.2. Binding of Th(IV) to HSA 
The interaction between Th(IV) and HSA has been studied using the DUS competition 
method in the presence of HSTf. This method is applicable for [HSA]<8.10-5 M, 
corresponding to about one eigth of the HSA concentration found in human serum. Above 
HSA concentrations of 8.10-5 M, the DUS competition method was no more applicable 
because the signal to noise ratio became too low. Experimental data are shown in Figure 3. In 
this range of HSA concentration, no significant complexation between Th(IV) and HSA was 
observed; although the absorbance of the Th(IV)-HSTf complex shows a decreasing trend 
with increase of [HSA], the decrease was not significant within experimental errors. The data 
show that interaction of Th(IV) with HSTf is stronger than with HSA: in the presence of eight 
times more HSA than of HSTf, Th(IV) remains bound to HSTf.  
 
3.2. Th(IV) speciation in human serum 
As mentioned in the introduction, the behaviour of Th in the presence of proteins and in 
serum has been studied by HPAEC with external ICP–MS analysis. Usual hyphenated 
techniques of speciation of trace elements in biological environment were reviewed by 
Lobinski et al. [33]. The data with good sensitivity were obtained, more often, by using the 
size–exclusion or reversed phase HPLC chromatography allowing species separation. Having 
also interest to identify free Th or complexed Th chemical forms, we have been working on 
anion–exchange chromatography with the detection done by ICP–MS general method. 
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On the basis of the results presented in the previous section, we expect that Th(IV) is mainly 
interacting with HSTf in human serum. An attempt to confirm this result is presented in this 
section both experimentally by HPAEC and theoretically. 
 
3.2.1. HPAEC–ICP–MS results 
Under non–perturbing conditions (the eluent corresponds to a physiological-type medium; 
pH=7.4, 0.1 M NaCl), the method allows the separation of HSA and HSTf proteins: HSTf is 
not retained (elution time = 2.5 min) while HSA is eluted as a broad peak at 10.5 min. The 
method has been tested for Th(IV) speciation in blood serum using physiological-type media. 
Figure 4 shows UV– and ICP–MS–chromatograms obtained with the different samples 
described in Table 1. Experiments were first realised in physiological–type media where the 
Th(OH)2(CO3)22- complex is the major Th(IV) species in solution. Only 0.5 % of Th(IV) 
could be eluted and no significant peak has been attributed to Th(OH)2(CO3)22- or detected in 
the time scale studied (1h30). A cleaning method with acidic solution (1 M HCl) was used to 
eliminate not restored Th(IV) after each experiment. The origin of this strong interaction is 
not known, but it will modify the equilibrium conditions controlling Th(IV) speciation in the 
injected solutions, as shown below. 
For the injection of the solution of Th(IV) pre-equilibrated with HSTf, the Th(IV) peak was 
detected at the position corresponding to the one of HSTf (Figure 4A,D). This corresponds to 
the direct signature of the complex formed and identified by DUS. However, only 6% of 
Th(IV) could be recovered (96% of this fraction being present with HSTf), while 80% of 
Th(IV) was initially bound to HSTf in the injected solution. A similar result was obtained in 
the presence of HSA, Th(IV) being eluted at the retention time of HSA between 10 and 15 
min (Figure 4A,D). 0.5% of the total concentration was recovered; 80% of this Th(IV) was 
found to be bound to HSA. Both Th(IV)–HSTf and Th(IV)–HSA complexes can therefore be 
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identified by HPAEC. The interaction strength between Th(IV) and the proteins is strong 
enough for avoiding a complete sorption of Th(OH)2(CO3)22- by equilibrium displacement on 
the resin. The percentage of eluted Th(IV) being less in the presence of HSA than in the 
presence of HSTf indicates that the stability constant is higher for HSTf than for HSA, in 
agreement with the results of the previous section. 
Th(IV) was next mixed with both proteins (HSTf and HSA) (Figure 4B,E). HSTf and HSA 
concentrations were fixed to mimic proteins concentrations in human serum (see Table 1). As 
in previous experiments, only a few percent of Th(IV) were eluted (10.5 %). 85% of Th(IV) 
content was found to be bound to HSTf, the rest was in interaction with HSA (15%). This 
distribution can be quantitatively calculated using the complexation constants describing 
Th(IV)/HSTf interaction and considering a complexation constant of 1017.5 for describing 
Th(IV)/HSA interaction. This estimated value was next used for the treatment of DUS 
experimental data (Figure 3A). As shown in Fig 3A, a slight decrease of the percentage of the 
Th(IV)–HSTf is predicted as the HSA concentration increases, although this trend could not 
be experimentally proven because of too high uncertainties associated to the absorbance 
measurements. 
Th(IV) speciation was next studied in human blood serum corresponding to the “real” 
biological system. After equilibration in the biological media for 24 hours, Th(IV) was eluted 
at the retention time between 3 and 5 min (9% eluted). Th(IV) appears to be well in 
interaction with HSTf, nevertheless no interaction with HSA was determined contrary to the 
observation in the synthetic system of Th(IV)/HSTf/HSA. This result is in agreement with 
Peter and Lehmann’s work reported that the Th was bound to HSTf in the serum of rat [8]. 
 
3.2.2. Modelling 
Both data obtained in vivo as well as the results of our study identify HSTf as the key 
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component governing Th(IV) speciation in blood serum. Similar to the study published on 
speciation of uranium in human blood serum [34], we wanted to verify these experimental 
results for trace concentrations of Th(IV) (10-9 M) in a predictive way by using the law of 
mass action principle. Due to the complexity of the human serum, the following 
simplifications were considered on the basis that the interaction strength of given serum 
components with Th(IV) will depend on their concentrations as well as on their 
equilibrium complexation constants: 
(i) all relevant inorganic ligands were taken into account (hydroxide, carbonate, 
phosphate, chloride, sulphate, nitrate) with the constants given in Table 2;  
(ii) for the low–molecular–weight organic components, only the citrate ion was 
considered (Table 2) as it is present in human serum at a relatively high concentration (1.6 
 10-4 M) and has a relatively high stability constant for Th(IV) complexation [25];  
(iii) both HSTf and HSA proteins were considered with the constants given in Figures 2 
and 3 captions; 
(iv) given the high affinity of iron for HSTf, we can safely consider that trace 
concentrations of Th(IV) can not compete with Fe(III) for HSTf binding sites. The number 
of available HSTf binding sites was therefore set to 70 % of the total capacity, 
corresponding to the fraction of HSTf not loaded with ferric ion [35]; 
(v) Ca was considered as a competitive metal ion for HSA sorption sites [28]. 
In agreement with experiments performed with blood serum, 99.9 % of Th(IV) is 
predicted bound to the protein pool, 99% being attached to HSTf. A less good agreement 
was obtained using Th(IV)/HSTf constants extrapolated from the relation of Sun et al. 
[14] reviewed by Ansoborlo et al. [29] (log K1=19.3 and log K2=18.2): the model 
predicted 48 % of Th(IV) under the form Th(OH)2(CO3)2-2, the rest being bound to HSTf. 
This shows that the extrapolation is misleading in the present case resulting in a 
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underestimation of Th(IV)/HSTf interaction. The values to be used and which can be 
recalculated from our data according to Eq. (2) are log K1 =21.2 and log K2=20.2. All the 
results show that HSTf is the key component governing Th(IV) speciation in blood serum. 
 
3.3. Potential of DTPA as chelating agent for Th(IV) in blood serum 
3.3.1. Theoretical considerations 
The DTPA ability to complex Th(VI) under biological conditions was first studied by DUS 
experiment in the physiological-type model medium (pH=7.4, 0.1 M NaCl) in the presence of 
HSTf. Complexation of Th(IV) with citrate was studied for comparison. The results of the 
titration curves are given in Figure 5. Whereas the citrate ion cannot compete with HSTf for 
Th(IV) in the whole range of ligand concentration studied (10-6 M – 3.5.10-4 M) (see Th(IV)–
citrate constant in Table 2 and complexation constants previously determined with HSTf), 
DTPA starts to complex Th(IV) at the concentration of 10-6 M to reach conditions where 
100% of Th(IV) is complexed with DTPA. An attempt of quantification was also done for the 
DTPA series. Since the recent NEA-OECD database does not propose any stability constant 
for Th/DTPA interaction, we have used two different quantitative models. The first one 
involves one complex ThL- with log K of 33.1 (=0) [17] whereas the second one considers 
different species proposed in the NIST database [18], i.e. ThL-, ThHL and ThOHL2- with 
thermodynamic constants recalculated at =0 (Table 2). The ThL- is the major species under 
studied experimental conditions. A good agreement between the experiment and the 
calculation was obtained for logK (ThL-) > 1029. This is in agreement with published 
constants and this allows an indirect validation of the complexation constants quantifying the 
interaction between Th(IV) and HSTf. We will next use the data from [17] for the 
simulations. 
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DTPA is a stronger chelating agent than citrate and its strong affinity for Th(IV) explains the 
application of this ligand as a decorporation agent [16]. Note that hydroxypyridone ligands 
appear more efficient than DTPA for in vivo decorporation of Th(IV) [4, 5]. In such an 
application, the amount of chelating agent is relatively important allowing to reach high 
concentrations at the injection points (about 0.01 M after injection of 200 mL of saline buffer 
considering a common dose of 30 µmol/kg body mass and a 70 kg person) and after dilution 
in the blood (~ 4.10-4 M for 5 L of blood volume) [36]. According to our simple model 
developed for the serum, the efficiency of complexation is predicted in vivo in both conditions 
with 100 % of Th(IV) bound to DTPA considering trace concentrations of Th(IV) (10-9 M). 
Taking into account the amount of ligand injected, we have neglected competition effects 
with trace metal ions but we have considered a possible competition with major cations using 
the DTPA/M2+ (M2+=Mg2+, Fe2+, Ca2+) constants and “free” blood concentrations (i.e. not 
bound to proteins) given in [18], and [29], respectively. The complexation with Th(IV) can 
thus occur and the complex can be eliminated naturally when used immediately after the 
contamination. 
The quantitative analysis show that the complexation becomes inefficient (~ 1% complexed) 
for a DTPA concentration of ≤10-5 M. It is worth saying that this inefficiency is not related to 
the HSTf vs DTPA competition but to the increasing competition with the divalent Fe2+, Mg2+ 
and Ca2+ ions as the ligand concentration decreases. When the Th(IV)/M(II) competition was 
not considered, the complexation remained efficient for trace DTPA concentration (10-9 M) 
with 71 % of Th(IV) complexed with DTPA. For TAT application, the concentration of 
injected chelate is usually about 10-9 M reaching a value around 5.10-11 M after dilution in the 
blood serum. Taking into account this concentration, DTPA will be inefficient to complex 
Th(IV) in vivo. 
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3.3.1. In vitro studies 
In vitro experiments have been carried out to assess the reliability of the above predictions. 
Th(IV) speciation was followed by ultrafiltration allowing the separation between low-
molecular (i.e. DTPA) and high-molecular (i.e. HSTf) weight compounds. Considering the 
sensitivity of the ICP-MS and the dilution required for the analysis, Th and DTPA 
concentrations were fixed at 5.10-7 M and 10-6 M, respectively. The concentrations are weak 
enough to expect an inefficient Th(IV) complexation (see the above section).  
Experimental results are shown in Figure 6. In the first experiment, Th(IV) is pre-equilibrated 
with serum before addition of DTPA. In agreement with the prediction, DTPA cannot catch 
Th(IV) in the blood serum. In the second experiment, DTPA was pre–equilibrated with 
Th(IV) in 0.1 M NaCl before addition in the human serum. The Th–DTPA complex appears 
surprisingly stable. This is explained by the strong kinetic stability of Th–DTPA complex: the 
reaction time is not sufficient to reach equilibrium conditions in the time scale studied (till 
five hours). Five hours correspond to about 10 half-lives of 226Th, the time for the 
radionuclide to “disappear”. Therefore, although DTPA cannot complex Th(IV) in vivo, it 
may be efficient to carry the radionuclide in TAT, when the biological molecule is being 
labelled before injection.  
 
4. Conclusion 
HSTf governs Th(IV) speciation in the blood serum. This was shown both experimentally and 
theoretically. Using the generally used Langmuir–type model, values of 1021.2 and 1020.2 were 
obtained for strong and weak sites, respectively. Although DTPA appears to be a good 
decorporation agent, the thermodynamic predicts that its concentration used in TAT is not 
sufficient to allow an efficient complexation of Th(IV). This inefficiency is surprisingly not 
related to the competition with HSTf but is related to the strong competition with major 
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divalent metal ions for DTPA. However, the high kinetic stability of Th–DTPA complex 
allows use of the ligand for synthesis of 226Th labeled biomolecules, when the complex is 
formed before injection. Studies on the stability and cytotoxicity of 226Th–DTPA–antibody 
contructs in vitro and in vivo are ongoing. 
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Table of Abbreviations 
 
DTPA diethylene triamine pentaacetic acid 
HSTf human serum transferrin 
HSA human serum albumin 
TAT targeted alpha therapy 
DUS difference ultraviolet spectroscopy 
HPAEC high-pressure-anion exchange 
chromatography 
NTA nitrilotriacetic acid 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
ICP-MS inductively conducted plasma - mass 
spectrometry 
 
 
 
:  
:  
:  
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Table 1: Experimental conditions 
Method [Th(IV)] (M) 
[HSTf] 
(M) 
carbonate Experiment Figure 
2.10-5 10-5 atmosphere NTA titration 1(B) 
2.10-6 10-6 atmosphere phosphate titration not shown
2.10-5 10-5 0 - 0,05 M carbonate titration 2(B) 
10-6 - 3,5.10-5 10-5 p(CO2) 1% Th(IV) titration 2(D) 
2.10-5 10-5 p(CO2) 1% competition with HSA (5.10-5-10-4 M) 3 
2.10-5 10-5 p(CO2) 1% competition with DTPA (7,5.10-7-10-4 M) 5 
 DUS  
2.10-5 10-5 p(CO2) 1% competition with citrate (7,5.10-7-5.10-4 M) 5 
2.10-5 10-5 p(CO2) 1% Th(IV)-HSTf interaction 4(A,D) 
2.10-5 - p(CO2) 1% Th(IV)-HSA (6.10-5 M) interaction 4(A,D) 
2.10-5 10-5 p(CO2) 1% competition with HSA (6.10-5 M) 4(B,E) 
HPEAC 
2.10-5 - p(CO2) 1% Th(IV)-serum interaction 4(C,F) 
2.10-5 10-5 p(CO2) 1% Th(IV) speciation in serum not shownultra-
filtration 2.10-7 - p(CO2) 1% in vitro studies in human serum with DTPA 6 
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Table 2: Formation of complexes between Th(IV) and low–molecular–weight ligands; 
equillibria relevant in the experimental conditions of this work and associated constants used 
for the modelling. Acid-base properties of the ligands can be found in the references. All 
constants are given at an ionic strength of I=0, 25°C. The values in italic are recalculated 
using the truncated Davies equation [26]. 
 
  species equilibrium reaction logK Ref 
Th(OH)4 Th4+ + 4 OH-  = Th(OH)4 -17.4 [24] 
(Th)4(OH)12+4 4Th4+ + 12H2O = (Th)4(OH)12+4 + 12H+  -26.6 [24] 
Th(OH)2(CO3)2-2 Th4+ + 2OH- +  2 CO32- = Th(OH)2(CO3)2-2 36.8 [24] 
Th(H2PO4)2+2 Th+4 + 2H3PO4 = Th(H2PO4)2+2 + 2H+ 6.2 [24] 
ThSO4+2  Th+4 + SO4-2 = ThSO4+2 6.2 [24] 
ThCl+3 ThCl+3 1.7 [24] 
inorganic 
ligands 
Th(NO3)+3 Th+4 + NO3- = ThNO3+3 1.3 [24] 
citrate ion ThL+ Th4+ + L-3 = ThL+ 15.7 [25] 
ThL- Th+4 + L-5 = ThL- 32.9 [18] 
ThLH ThL- + H+ = ThLH 2.37 [18] 
ThLOH-2 Th+4 + L-5 + H2O= ThLOH-2 + H+ 23.6 [18] 
DTPA 
ThL+ Th+4 + L-5 = ThL- 33.1 [17] 
ThL+ Th+4 + L-3 = ThL+ 17.1 [26] 
NTA 
ThL2-2 ThL+ + L-3 = ThL2-2 14.2 [26] 
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Figure 1: Complexation of Th(IV) as a function of NTA concentration. Experimental 
conditions and parameters used for the modelling with low–molecular weight compounds are 
summarized in Tables 1 and 2, respectively. (A) Th(IV) speciation calculated in the absence 
of HSTf. (B) Absorbance measured as a function of NTA concentration and comparison with 
literature data [12]. (C) Comparison between experimental data and modelling considering 
one NTA (solid line; log K1 = 31, log K2 = 30) and two NTA (dotted line; log K1 = 41, log K2 
= 40) acting as synergistic anions. L3- stands for deprotonated NTA. 
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Figure 2: Complexation of Th(IV) by HSTf in the presence of carbonates. Experimental 
conditions and parameters used for the modelling with low–molecular–weight compounds are 
summarized in Tables I and II, respectively. (A) Th(IV) speciation calculated in the absence 
of HSTf. (B) Absorbance measured as a function of carbonate concentration. (C) Comparison 
between experimental data and modelling considering one carbonate (dotted line; log K1 = 27, 
log K2 = 26) and two carbonates (solid line; log K1 = 33.5, log K2 = 32.5) acting as synergistic 
anions. (D) Absorbance measured as a function of the ratio (r) between total Th and HSTf 
concentrations. The line represents the simulation made with log K1 = 33.5, log K2 = 32.5 and 
(obs ) = 60  103 M-1 cm-1. 
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Figure 3:  Competition between HSTf and HSA followed by DUS. Experimental conditions 
and parameters used for the modelling with low-molecular weight compounds are 
summarized in Tables 1 and 2, respectively. Th(IV)/HSTf interaction was described 
considering two carbonates bound with log K1 = 33.5 and log K2 = 32.5. Th(IV)/HSA 
interaction was described using a Langmuir–type model with K = 1017.5. 
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Figure 4: UV– (A,B,C) and ICP–MS– (D,E,F) chromatograms determined by HPAEC. See 
Table 1 for the experimental conditions. Eluent = 0.1 M NaCl, 2.10-3 M PBS, pH 7.4, 1% 
CO2. 
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Figure 5: Competition between HSTf and DTPA and citrate followed by DUS. Experimental 
conditions and parameters used for the modelling with low–molecular–weight compounds are 
summarized in Tables 1 and 2, respectively. Th(IV)/HSTf interaction was described 
considering two carbonates bound with log K1 = 33.5 and log K2 = 32.5.  
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Figure 6: Stability of Th–DTPA complex in the serum followed by ultrafiltration as a 
function of the time. DTPA and Th concentration were fixed at 10-6 and 5.10-7 M, 
respectively. ( ) Th–DTPA was pre–formed before addition in the serum. (O) Th was added 
in the serum containing DTPA. 
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